Similar articles for PMID: 36657979

Year	Number of Results
2002	2
2004	6
2006	1
2008	1
2009	2
2010	3
2011	3
2012	7
2013	7
2014	3
2015	5
2016	6
2017	5
2018	10
2019	12
2020	13
2021	22
2022	20
2023	1

1

Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the ⁶⁸Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer.

von Guggenberg E, Uprimny C, Klingler M, Warwitz B, Sviridenko A, Bayerschmidt S, Di Santo G, Virgolini IJ. von Guggenberg E, et al. J Nucl Med. 2023 Jan 19:jnumed.122.264977. doi: 10.2967/jnumed.122.264977. Online ahead of print. J Nucl Med. 2023. PMID: 36657979

2

DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.

Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, Decristoforo C, Virgolini I, von Guggenberg E. Klingler M, et al. J Nucl Med. 2019 Jul;60(7):1010-1016. doi: 10.2967/jnumed.118.221283. Epub 2018 Dec 7. J Nucl Med. 2019. PMID: 30530828 Free PMC article.

3

¹¹¹In/⁶⁸Ga-Labeled DOTA-conjugated cyclo[γ-d-Glu-Ala-Tyr-d-Lys]-Trp-Met-Asp-Phe-NH₂ (cyclo-MG1), a minigastrin analog.

Chopra A. Chopra A. 2012 May 17 [updated 2012 Jul 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 May 17 [updated 2012 Jul 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 22787691 Free Books & Documents. Review.

4

Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog ¹⁷⁷Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?

Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M. Sauter AW, et al. J Nucl Med. 2019 Mar;60(3):393-399. doi: 10.2967/jnumed.118.207845. Epub 2018 Jul 12. J Nucl Med. 2019. PMID: 30002107 Free article.

5

¹¹¹In/⁶⁸Ga-Labeled DOTA conjugated cyclo[γ-d-Glu-Ala-Tyr-d-Lys]-Trp-Nle-Asp-Phe-NH₂ (cyclo-MG2), a minigastrin analog.

Chopra A. Chopra A. 2012 May 17 [updated 2012 Jul 26]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 May 17 [updated 2012 Jul 26]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 22855967 Free Books & Documents. Review.

6

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

7

Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.

Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R, Putzer D, Gabriel M, Virgolini I. Traub-Weidinger T, et al. Q J Nucl Med Mol Imaging. 2010 Feb;54(1):52-60. Q J Nucl Med Mol Imaging. 2010. PMID: 20168286 Free article. Clinical Trial.

8

Radiopharmaceutical Formulation and Preclinical Testing of ⁶⁸Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial.

Hörmann AA, Klingler M, Rangger C, Mair C, Decristoforo C, Uprimny C, Virgolini IJ, von Guggenberg E. Hörmann AA, et al. Pharmaceuticals (Basel). 2021 Jun 16;14(6):575. doi: 10.3390/ph14060575. Pharmaceuticals (Basel). 2021. PMID: 34208516 Free PMC article.

9

PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In.

Roosenburg S, Laverman P, Joosten L, Cooper MS, Kolenc-Peitl PK, Foster JM, Hudson C, Leyton J, Burnet J, Oyen WJ, Blower PJ, Mather SJ, Boerman OC, Sosabowski JK. Roosenburg S, et al. Mol Pharm. 2014 Nov 3;11(11):3930-7. doi: 10.1021/mp500283k. Epub 2014 Jul 11. Mol Pharm. 2014. PMID: 24992368

10

Comparison of PET/CT imaging with [¹⁸F]FDOPA and cholecystokinin-2 receptor targeting [⁶⁸Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma.

Uprimny C, von Guggenberg E, Svirydenka A, Mikołajczak R, Hubalewska-Dydejczyk A, Virgolini IJ. Uprimny C, et al. Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):935-936. doi: 10.1007/s00259-020-04963-z. Epub 2020 Aug 3. Eur J Nucl Med Mol Imaging. 2021. PMID: 32748048 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed